Boehringer-Ingelheim v. USV Pvt. Ltd.: Consent Judgment Blocks Generic JARDIANCE® Entry
Boehringer-Ingelheim sued Indian generic manufacturer USV Pvt. Ltd. in Delaware District Court over four patents covering empagliflozin (JARDIANCE®). The case resolved in 162 days via consent judgment — confirming patent validity and imposing a permanent injunction barring USV’s ANDA product from the U.S. market until all four patents expire.
Four Empagliflozin Patents Upheld as USV Concedes in Delaware ANDA Dispute
Boehringer-Ingelheim filed suit on 10 July 2025 in the District of Delaware before Judge Colm F. Connolly, asserting infringement of four patents — US8551957B2, US11090323B2, US11833166B2, and US12115179B2 — all directed to empagliflozin, the active ingredient in the blockbuster SGLT2 inhibitor JARDIANCE®. The defendant, USV Pvt. Ltd., an Indian pharmaceutical company, had filed an ANDA seeking FDA approval to market 10 mg and 25 mg empagliflozin tablets in the United States before the Boehringer patents expired.
The case closed on 19 December 2025 via a consent judgment — a negotiated court order in which USV effectively conceded the validity and enforceability of all four patents with respect to its ANDA product. The court entered a permanent injunction barring USV, its affiliates, agents, and successors from manufacturing, selling, offering for sale, importing, or distributing its generic empagliflozin tablets in the U.S. until the last of the four patents expires, including any patent term extension, adjustment, or pediatric exclusivity. The complaint was simultaneously dismissed with prejudice, and each party agreed to bear its own fees and costs.
Resolution in 162 days is notably swift for Hatch-Waxman ANDA litigation, which typically proceeds on 30-month stay timelines. The speed of the consent judgment suggests the parties likely reached a parallel licensing or market-entry agreement — the terms of which are not reflected in the public record. The injunction carves out any future authorisation Boehringer may separately grant USV, which is a standard feature of authorised generic arrangements. The court explicitly retained jurisdiction to enforce the consent judgment, signalling that any future commercial relationship between the parties remains judicially supervised.
Filing to Consent Judgment in 162 days
Resolved in 162 days — well below median ANDA patent trial timelines, suggesting early negotiated resolution
Consent judgment entered: what the ruling means for both parties
Consent judgment: patent validity conceded by agreement
A consent judgment is a court-entered order reflecting a negotiated resolution — here, USV agreed not to contest validity or enforceability of all four Boehringer empagliflozin patents as applied to its ANDA product. Unlike a litigated outcome, a consent judgment does not generate binding precedent on claim construction or validity, but it is judicially enforceable as an order of the court. The court retains jurisdiction to enforce compliance.
Negotiated court orderBoehringer secures injunction covering all four patent families
Boehringer-Ingelheim obtained its principal commercial objective: a permanent injunction blocking USV’s generic empagliflozin from the U.S. market until expiry of all four asserted patents, plus any extensions or pediatric exclusivity. The judgment also preserves Boehringer’s ability to grant USV a future authorised-generic licence, and allows Boehringer to return to court if further regulatory exclusivities arise. JARDIANCE® market exclusivity is effectively maintained against this particular challenger.
Injunction granted; market exclusivity maintainedUSV’s U.S. launch blocked pending patent expiry
USV Pvt. Ltd. is enjoined from commercialising its 10 mg and 25 mg empagliflozin ANDA product in the United States through the life of all four patents. The consent judgment binds USV’s successors and assigns, limiting the value of the ANDA to any third-party acquirer. However, the explicit carve-out for Boehringer-granted authorisation suggests the parties may have negotiated a separate commercial arrangement — a possibility consistent with Boehringer’s pattern in other ANDA settlements, though no such agreement is confirmed in the public record.
ANDA launch blocked; authorised generic possibleJARDIANCE® IP fortress reinforced across four patent generations
The four asserted patents span application dates from 2010 (US8551957B2) through to a 2023 application (US12115179B2), suggesting Boehringer has layered patent protection that extends well into the future. Other ANDA filers targeting empagliflozin face a reinforced litigation posture: each consent judgment strengthens Boehringer’s negotiating leverage in subsequent disputes. For SGLT2 inhibitor competitors and generic manufacturers evaluating empagliflozin ANDA strategies, this outcome signals high settlement pressure and robust exclusivity.
Multi-layered SGLT2 inhibitor IP portfolioFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Boehringer-Ingelheim | Individual | Global pharmaceutical innovator — holder of US8551957B2, US11090323B2, US11833166B2 & US12115179B2 covering empagliflozinSearch in Eureka ↗ |
| Defendant | USV Pvt., Ltd. | Company | Indian generic pharmaceutical manufacturer seeking U.S. ANDA approval for 10 mg and 25 mg empagliflozin tabletsSearch in Eureka ↗ |
| Plaintiff counsel | Brian P. Egan | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff counsel | Megan Elizabeth Dellinger | Attorney | Counsel for Boehringer-IngelheimSearch in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Boehringer-IngelheimSearch in Eureka ↗ |
| Defendant counsel | Kelly E. Farnan | Attorney | Counsel for USV Pvt., Ltd.Search in Eureka ↗ |
| Defendant counsel | Sara M. Metzler | Attorney | Counsel for USV Pvt., Ltd.Search in Eureka ↗ |
| Defendant law firm | Richards Layton & Finger PA | Law Firm | Representing USV Pvt., Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consent judgment language is unusually comprehensive for a negotiated resolution: it expressly validates all four patents, grants a permanent injunction binding USV’s successors and assigns, and preserves Boehringer’s right to seek modifications for future regulatory exclusivities. The phrase ‘solely with respect to the manufacture, use, sale, offer for sale, and importation of the USV ANDA Product’ confines the validity finding to USV’s specific product, meaning the order does not constitute a broadly applicable adjudication of patent validity against other ANDA filers. The dismissal with prejudice forecloses USV from re-litigating these claims.
US8551957B2, US11090323B2, US11833166B2 & US12115179B2 — empagliflozin SGLT2 inhibitor patent portfolio
The four asserted patents — US8551957B2 (application filed 2010), US11090323B2, US11833166B2, and US12115179B2 (application filed 2023) — collectively protect empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor marketed as JARDIANCE®. SGLT2 inhibitors block glucose reabsorption in the kidney, lowering blood sugar and — as later demonstrated — providing significant cardiovascular and renal benefits. The multi-generational application dates suggest the portfolio spans core composition claims through to formulation and manufacturing refinements, a classic lifecycle management strategy in branded pharmaceutical IP.
Empagliflozin is one of Boehringer-Ingelheim’s highest-revenue products globally, with JARDIANCE® indicated for type 2 diabetes, heart failure, and chronic kidney disease. The breadth of the four-patent stack — and Boehringer’s willingness to litigate all four simultaneously — signals that this portfolio will anchor enforcement actions against every subsequent ANDA filer. Generic manufacturers, biosimilar developers, and formulators working in the SGLT2 inhibitor space face an entrenched IP landscape that will require careful FTO analysis across each patent family before any commercialisation decision.
Should your team run an FTO against the JARDIANCE® empagliflozin patent portfolio?
Any R&D team developing empagliflozin generics, SGLT2 inhibitor combinations, or competing tablet formulations should treat this case as a direct signal to conduct a comprehensive freedom-to-operate analysis before investing in ANDA preparation or manufacturing scale-up. With four active patents — including a 2023 application that may carry a long effective life — the risk of entering the U.S. market without clearance analysis is commercially significant. This is particularly true for formulators of 10 mg and 25 mg solid oral dosage forms, which are exactly the product configurations enjoined in this case.
PatSnap Eureka’s FTO Search Agent allows IP and R&D teams to map all four asserted patents against a proposed product formulation, identify claim scope for each family, and surface prior art that could support future IPR or PGR petitions. Eureka’s citation and family tracking tools also flag continuation applications and pending claims that may extend exclusivity beyond the currently issued patents — critical intelligence for any generic manufacturer modelling empagliflozin launch windows.
Run a freedom-to-operate analysis on US11833166B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA empagliflozin and SGLT2 inhibitor patent cases in U.S. courts
Cases involving empagliflozin ANDA disputes and SGLT2 inhibitor patent enforcement in Delaware District Court and related U.S. federal venues.
What this case signals for the SGLT2 inhibitor and ANDA litigation landscape
Boehringer’s rapid consent judgment reinforces the commercial durability of JARDIANCE® and sets a precedent for how generic challengers weigh empagliflozin ANDA economics.
Four-patent stack signals Boehringer’s layered exclusivity strategy
Asserting patents spanning application dates from 2010 to 2023 reflects deliberate lifecycle management. Generic filers must invalidate or design around multiple overlapping claim sets — not just the earliest composition patent. IP teams monitoring SGLT2 inhibitor freedom-to-operate should map all four patent families before advancing empagliflozin ANDA strategies.
162-day resolution suggests underlying commercial deal
Consent judgments in ANDA cases resolved this quickly typically accompany confidential authorised-generic or market-entry agreements. The judgment’s explicit authorisation carve-out is consistent with this pattern. Competitors and payers tracking JARDIANCE® generic entry timelines should monitor FDA Orange Book listings and any authorised-generic notifications from Boehringer closely.
Boehringer-Ingelheim v USV — key questions answered
The consent judgment held that Boehringer’s four empagliflozin patents (US8551957B2, US11090323B2, US11833166B2, US12115179B2) are valid and enforceable against USV’s ANDA product, and permanently enjoined USV from marketing its 10 mg and 25 mg generic empagliflozin tablets in the U.S. until all four patents expire, including any extensions.
No — the validity finding is expressly limited to USV’s specific ANDA product. The order does not constitute a binding adjudication of patent validity against other ANDA applicants. However, it signals Boehringer’s enforcement posture and willingness to litigate all four patent families, which is likely to influence settlement calculations for other generic challengers.
Boehringer asserted US8551957B2, US11090323B2, US11833166B2, and US12115179B2 — a portfolio covering empagliflozin compositions and formulations spanning application dates from 2010 to 2023, reflecting a layered lifecycle management strategy for JARDIANCE®.
The case resolved in 162 days — well below typical ANDA patent litigation timelines. Such speed in Hatch-Waxman cases typically suggests the parties reached a parallel commercial agreement (e.g., an authorised-generic licence or negotiated market-entry date) alongside the consent judgment. The public record does not confirm any such agreement, but the judgment’s explicit authorisation carve-out is consistent with this pattern.
USV is enjoined from commercialising its ANDA product until all four patents expire, including patent term extensions and pediatric exclusivity. The consent judgment explicitly carves out the possibility of Boehringer granting USV specific authorisation, which could allow an authorised-generic arrangement at Boehringer’s discretion. Without such authorisation, USV cannot enter the U.S. market.
PatSnap Eureka searches patents and litigation data to answer instantly.